Please login to the form below

Not currently logged in
Email:
Password:

biosimilars

This page shows the latest biosimilars news and features for those working in and with pharma, biotech and healthcare.

Roche preps new Kadcyla filings after phase 3 trial win

Roche preps new Kadcyla filings after phase 3 trial win

That will help support the $10bn-plus franchise as Herceptin faces the threat of biosimilar competition in some European markets, including the UK.

Latest news

More from news
Approximately 129 fully matching, plus 302 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 11 fully matching, plus 50 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest from PMHub

  • Biosimilars: Getting the flock to market

    The factor that drives the success of biosimilars is value. The biosimilar dividend is that more patients can get access to the high-value treatments they need. ... Luckily, the biosimilar path has already been trodden, so new agents can slipstream the

  • Webinar: What next for biosimilars?

    Webinar: What next for biosimilars? Tuesday 19th July 15:00 BST/10:00 EDT/16:00 CEST. ... Join market research consultants Laurent Chanroux and Richard Head for this complimentary webinar in which they will explore and compare biosimilars in RA and

  • Video: Global Biosimilars Market

    Video: Global Biosimilars Market. Research director of Therapy Watch, Laurent Chanroux, discusses the growth opportunities for biosimilars and the importance of adaptable market tracking for pre and post product launch. ... It is predicted that

  • Tackling biosimilars – how to handle the threat to Pharma brands

    Strategy Consultant Mark Assenti talks through three key points for developing a strategy to tackle biosimilars. ... Therefore, while the biosimilar drugs may be very similar, they will never be identical.

  • Free Thinking: Are biosimilars the answer to the rising cost of RA treatment?

    Free Thinking: Are biosimilars the answer to the rising cost of RA treatment? ... With Enbrel biosimilar Benepali about to launch across EU, we ask what’ s next for RA?

More from PMHub
Approximately 17 fully matching, plus 29 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics